At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 9 enrolled
Drug / intervention
Aflibercept every 2 months +1 moredrug
Likely dose
Aflibercept every 2 months 2.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Radiation Retinopathy With Intravitreal Aflibercept Injection 2.0mg
In Brief
A Phase 1 clinical trial evaluating Aflibercept every 2 months and Aflibercept monthly for Radiation Retinopathy and Macular Edema. Completed, enrolled 9 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess the safety of intravitreal aflibercept injection - in the treatment of macular edema associated with retinopathy secondary to previous radiation therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRadiation Retinopathy, Macular Edema
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartNov 2012
Primary CompletionJan 2019
Study CompletionMar 2019
TodayJul 2026
First PostedApr 18, 2012
Enrollment StartNov 1, 2012
Primary CompletionJan 1, 2019
Study CompletionMar 27, 2019
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 14.2 years ago
Interventions
Aflibercept every 2 monthsdrug
2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
Aflibercept monthlydrug
2.0mg aflibercept intravitreal injections every month (M0-11)